AU668160B2 - Preparation useful for prevention and treatment of intestinal infections in animals and human beings - Google Patents
Preparation useful for prevention and treatment of intestinal infections in animals and human beings Download PDFInfo
- Publication number
- AU668160B2 AU668160B2 AU39810/93A AU3981093A AU668160B2 AU 668160 B2 AU668160 B2 AU 668160B2 AU 39810/93 A AU39810/93 A AU 39810/93A AU 3981093 A AU3981093 A AU 3981093A AU 668160 B2 AU668160 B2 AU 668160B2
- Authority
- AU
- Australia
- Prior art keywords
- bacteria
- animals
- sodium
- human beings
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000002360 preparation method Methods 0.000 title claims description 11
- 241001465754 Metazoa Species 0.000 title claims description 9
- 241000282414 Homo sapiens Species 0.000 title claims description 6
- 238000011282 treatment Methods 0.000 title claims description 5
- 206010022678 Intestinal infections Diseases 0.000 title claims description 4
- 230000002265 prevention Effects 0.000 title claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 11
- 239000010903 husk Substances 0.000 claims description 9
- 229910001414 potassium ion Inorganic materials 0.000 claims description 9
- 229910001415 sodium ion Inorganic materials 0.000 claims description 9
- 235000003421 Plantago ovata Nutrition 0.000 claims description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000009223 Psyllium Substances 0.000 claims description 7
- 229940070687 psyllium Drugs 0.000 claims description 7
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 241001499741 Plantago arenaria Species 0.000 claims 1
- 241000894006 Bacteria Species 0.000 description 22
- 239000000203 mixture Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 10
- 244000134552 Plantago ovata Species 0.000 description 7
- 238000011534 incubation Methods 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229960000907 methylthioninium chloride Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 241001135228 Bacteroides ovatus Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 231100000249 enterotoxic Toxicity 0.000 description 1
- 230000002242 enterotoxic effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Applicant(s): PHARMALETT DANMARK A/S Invention Title: PREPARATION USEFUL FOR PREVENTION AND TREATMENT OF INTESTINAL INFECTIONS IN ANIMALS AND HUMAN BEINGS
C
C. C C
C
The following statement is a full description of this invention, including the best method of performing i.t known to me/us: PREPARATION USEFUL FOR PREVENTION AND TREATMENT OF INTESTINAL INFECTIONS IN ANIMALS AMD HUMAN BEINGS Background of the Invention It is known that Psyllium Husk (also known as Isphagula Husk), in common with many other compounds, such as charcoal, kaolin, and pectins, is capable of binding bacteria to some extent.
To the best of our knowledge, this is a physical binding, similar to the adsorption of chemicals to the surface of activated charcoal. It is also known that divalent ions may increase the adhesion of bacteria to pectins. In this context, it will be clearly understood that adsorption 15 means adhesion to a surface, as distinct from absorption in which something is absorbed into the interior of the absorbing material. To the best of our knowledge, the prior art contains no description of the above substances being capable of adsorbing very effectively some bacteria 20 in preference to others, with the help of a combination of monovalent ions.
ooo Intestinal Flora Normally, many different types of bacteria are present in 25 the intestinal canal. Some are harmless and are important *o in homeostasis, while others are pathogenic or potentially pathogenic under certain conditions. The pathogenic organisms may be present in the intestinal canal of the host in a "dormant state", and do not become pathogenic until they are exposed to some influence, such as for example stress, change of foodstuffs or virus infection.
Two types of pathogenic bacteria present in the intestinal canal are of particular interest: 1) the invasive bacteria that infiltrate into the blood of the host organisms causing septicaemia, and 2) the toxin producing bacteria, that cause toxaemia.
The coliforms and in particular Entero Toxic E. coli (ETEC) that produce colitoxin are of special interest in the present invention.
An activated ETEC is mobile,'and seeks the internal surface of the intestine and adheres to a receptor on the surface of the intestinal wall where it starts to produce toxin.
It is the toxin that is dangerous as in its presence it is 15 more difficult and sometimes no longer possible for the host animal to retain water in the intestinal canal, nor to absorb water or nourishment therefrom. As a result the animal host will dehydrate and in many cases die. Known agents for treatment of this condition include Diaproff 20 (see U.S. patent 5,038,396).
Standard treatments of ETEC and other undesirable bacteria include prophylaxis by administering small amounts of antibiotics in the feedstuff to control the infection, or 25 to reduce the pH of the intestinal canal by means of various acids administered orally. Improving hygiene is also of assistance.
Alternatively, or in addition to the foregoing, therapeutic doses of antibiotics may be given by injection or orally to kill the undesirable bacteria. However, such administration of antibiotics is not specific to the undesirable bacteria, and will kill all bacteria, including 4 the bacteria normally residing in the intestine which are protective of the host, resulting in further complications.
The Invent ion We have found that administration of Psyllium Husk combined with sodium and potassium ions, is unexpectedly effective in binding ETEC.
Although we do not wish to be limited by any hypothetical or postulated mechanism for the observed beneficial effects, we believe that Psyllium Husk in the presence of sodium and potassium ions selectively adsorbs undesirable bacteria and in particular coliforms such as ETEC from the intestinal contents to such an extent that the solution 15 will be almost totally purified therefrom, while at the *same time the normal intestinal flora are substantially unaffected. Although the addition of either sodium or potassium ions has some effect, we have found that by adding both sodium and potassium ions simultaneously, we 20 achieve a synergistic effect exceeding the additive effective of either sodium or potassium ions independen~tly.
The compositIon of Psyllium Husk containing the said sodium and potassium ions may be administered either dry or suspended in water, and may further be used in combination 25 with other biological, organic or inorganic active substances.
The breaking out of diarrhoea is thus prevented by selective removal of the undesirable bacteria, such as ETEC from the site, leaving the normal flora unaffected, and thus optimwum conditions of growth and continuing heal~ily existence of the animal are secured. The present invention greatly reduces the need for consumntion of antibiotics and by doing so also minimises the attendant problem of the generation of antibiotic resistant bacteria that may be potentially pathogenic under certain conditions.
Detailed Description of the Invention Psyllium Husk, also known as Isphagula Husk, hereinafter referred to as PH, contains mucopolysaccarides which in combination with water form a gel (see British Pharmacopaeia 1980, vl. 2:246-247). The MP consist of a polyxylose backbone with side chains containing galactose, mannose, glucose, fructose, rhamnose and arabinose (see Sandh, J.S. 1981. The gel structure of carbohydrate of Isphagula husk ex Plantago ovata Forsk. Carbohydr. Res.
93:247-259, and Dzuyuba, N.P. et al. 1977, Estab3ishment of S" 15 the qualitative and quantitative composition of the polysaccharide of vegetal material and preparations by physico chemical methods Farm Zh. 32: 56-59). The polyxylose backbones are resistant to breakdown by intestinal bacteria or enzymes, with the exception of 20 Bacteroides ovatus (see Salyers. D. at al. 1978, Breakdown of Psyllium hydrocelloid by Strains of Bacteroides ovatus from the human intestinal tract, Can. J. Mic'obiol. 24: 336-338).
25 Isphagula has been used in the past as a local traditional medicine against diarrhoea (see Singh, B.H. 1940 Indian Med. Gaz.: 733).
More recently it has been shown that PH added to electrolyte glucose mixtures stimulates the absorption of glucose and consequently stimulates rehydration in dehydrated animals and humans patent 5,038,396).
We have found that PH together with a combination of sn'41c 6 and potassium ions is far more effective that PH alone. It is believed that this is due to an improved affinity for pathogens which are selectively adsorbed, avoiding the disadvantages of the prior art.
Examples The bacterial strains used in this study was E. coli K88ab (ETEC strains).
Four solutions were made: Solution PH was made in Nutrient Broth (Oxoid CM) and tap water (1 gram/15 ml).
15 Solution was made as solution however 80 mmol/L sodium was added as sodium chloride.
Solution was made as solution however 15 mmol/L potassium was added as potassium chloride.
Solution was made as solution however 80 mmol/L sodium and 15 mmol/L potassium was added as sodium chloride and potassium chloride.
25 In general bacterial suspensions containing 50 million colony forming units per ml were made.
Qualitative adherence Equal amounts of the solutions and bacterial suspensions were homogenized and incubated aerobically at 37 0
C
0.1 0 C) in a water bath. The suspensions were gently shaken for 15 min. Just before and during incubation samples were taken at regular intervals from the bacteria/solution mixtures.
7 Adherence to PH particles was determined in both native preparations under phase contrast microscope and methyleneblue stained preparations under normal light microscope with 400 and 1000 times magnification (Zeiss, 40 and 100 phase-contrast and standard oil jimersion lenses).
Semi-q-uantitative adherence Centrifugation was used to separate the bacteria-PH mixtures into a precipitation fraction containing bacteria adhered to PH and a supernatant fraction with only free bacteria. The PH-bacteria mixtures were centrifugated (Labofuge GL, radius=150 mm) in 10 ml tubes at 600 rpm for 15 min. Before and after centrifugation the optical density of the mixtures and the supernatants were 15 measured (wavelength 541 nm). The difference in optical :::o:density before and after centrifugation is a semi quiantitative measure for the numbers of bacteria adhered to PH particles.
20 The precipitates were resuspended in the original volumes to measure the optical density. Besides, native and methylene-blue stained preparations were made for (phasecontrast) miscroscopy to verify the findings.
25 Results Qualitative adherence The results showed that the adherence of E. coli K88ab to PH particles started after 2 hours of incubation. The adherence was most pronounced for the mixture containing sodium and potassium ions in comparison with the other mixtures.
After three hours the difference between mixture was even more pronounced. Mixture showed the least I I 8 adherence, mixture and did increase the adherence to some extent. The methylene-blue stained slides confirmed the findings of the native preparations.
Semi-quantitative adherence Table 1. Optical density before and after 3 hours incubation of the ;inxtures the supernatants after centrifugation and the difference between and Before incubation After incubation M S M-S M S M-S *o e SMixture 0.98 0.83 0.15 0.96 0.69 0.27 15 Mixture 1.13 0.97 0.16 1.02 0.51 0.51 Mixture 1.15 0.98 0.17 1.16 0.58 0.58 Mixture 1.05 0.93 0,12 1.10 0.14 0.96 Before and after incubation the optical densities of the 20 mixtures and the supernatants were measured in duplicate.
The results indicate that mixture shows strong adherence capability; the supernatant is almost clear of the ETEC E. coli.
Obviously the combination of sodium ions and po'assium ions strongly enhance the capability of the PH particles to adhere to the bacteria. It is envisaged that this combination can replace antibiotics in a lot of cases, such as in medicated feeds.
It is possible that this combination, by strongly adhering to the bacteria, prevents such bacteria from docking onto I 9 the receptor on the surface of the intestinal wall. This .may be as a result of acting as a receptor analogue.
We do not however wish to be limited by any hypothetical or postulated mechanism for the observed beneficial effects of this combination.
9
Claims (3)
- 2. A preparation according to claim 1 wherein the sodium containing substances and potassium containing substances comprise sodium chloride and potassium chloride.
- 3. A method of preventing and treating animals or human beings suffering from intestinal infections which 15 comprises administering thereto a preparation according to S* any one of claims 1 to 2. DATED THIS 22ND DAY OF FEBRUARY 1996 PHARMLETT DANMARK A/S O0 By Its Patent Attorneys: S 20 GRIFFITH HACK CO., 1 Fellows Institute of Patent 0 Attorneys of Australia a statvhrordkeepspeciPHARM.OANMARK 22.2 ABSTRACT A preparation useful for prevention and treatment of intestin...l infections in animals and human beings, comprises Psyllium Husk together with sodium and potassium ions, for example in the form of sodium chloride and potassium chloride. 4* 4**4 4 44*4 4*404s 4 4 *4 4 4 4* *444 6*
- 4. 4 .4 @4 44 4 4 4. 44 .4 4 0 4%Q* 0 44 4. 4 44 44 4 .44 4 4444 4 4444 44 44 4 .4,4 *4 4 44 0 44
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU39810/93A AU668160B2 (en) | 1993-05-26 | 1993-05-26 | Preparation useful for prevention and treatment of intestinal infections in animals and human beings |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU39810/93A AU668160B2 (en) | 1993-05-26 | 1993-05-26 | Preparation useful for prevention and treatment of intestinal infections in animals and human beings |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3981093A AU3981093A (en) | 1994-12-15 |
| AU668160B2 true AU668160B2 (en) | 1996-04-26 |
Family
ID=3726890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU39810/93A Ceased AU668160B2 (en) | 1993-05-26 | 1993-05-26 | Preparation useful for prevention and treatment of intestinal infections in animals and human beings |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU668160B2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2897284A (en) * | 1983-06-02 | 1984-12-06 | Ciba-Geigy Ag | Easily dispersible dietary fibre product |
| AU3390584A (en) * | 1983-10-03 | 1985-04-23 | Gjerlov Mogens | Preparation for rehydrating monogastric animals,including human beings,suffering from diarrhoea and use thereof |
| AU6086890A (en) * | 1989-08-10 | 1991-02-14 | Procter & Gamble Company, The | Agglomerated psyllium husk containing edible acid |
-
1993
- 1993-05-26 AU AU39810/93A patent/AU668160B2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2897284A (en) * | 1983-06-02 | 1984-12-06 | Ciba-Geigy Ag | Easily dispersible dietary fibre product |
| AU3390584A (en) * | 1983-10-03 | 1985-04-23 | Gjerlov Mogens | Preparation for rehydrating monogastric animals,including human beings,suffering from diarrhoea and use thereof |
| AU6086890A (en) * | 1989-08-10 | 1991-02-14 | Procter & Gamble Company, The | Agglomerated psyllium husk containing edible acid |
Also Published As
| Publication number | Publication date |
|---|---|
| AU3981093A (en) | 1994-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Czerucka et al. | Experimental effects of Saccharomyces boulardii on diarrheal pathogens | |
| Papini et al. | Bafilomycin A1 inhibits Helicobacter pylori‐induced vacuolization of HeLa cells | |
| DE69533593T2 (en) | PREPARATIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDER CONTAINING ARABINOGALACTAN AND POLYPHENOLS OF LARIX. | |
| Ramesh et al. | Prevention of Clostridium difficile-induced ileocecitis with bacteriophage | |
| US20080089942A1 (en) | Use of adsorbent carbon microspheres to treat intestinal bacterial infections | |
| AU590578B2 (en) | Treatment of non-ulcer dyspepsia with bismuth salts | |
| CN1117585C (en) | Nisin combined with monolaurin with anti-helicobacter activity | |
| EP0623024B1 (en) | Pharmaceutical bacteriocin compositions and their use for treating gastrointestinal disorders | |
| Choi et al. | Effect of apitherapy in piglets with preweaning diarrhea | |
| CN107259203A (en) | Application of trichoderma in preparation of feed and/or preparation for treating or preventing vibrio infection of shrimps | |
| AU668160B2 (en) | Preparation useful for prevention and treatment of intestinal infections in animals and human beings | |
| ES2290195T3 (en) | USE OF CARBON HYDRATES TO ELIMINATE INTESTINAL INFECTIONS IN ANIMALS. | |
| Yokochi et al. | Differential release of smooth-type lipopolysaccharide from Pseudomonas aeruginosa treated with carbapenem antibiotics and its relation to production of tumor necrosis factor alpha and nitric oxide | |
| EP2486943B1 (en) | Pharmaceutical composition for use in the prophylaxis and treatment of infectious and non-infectious diarrhoea | |
| Glavin et al. | Evidence of “cross-stressor”-induced adaptive gastric cytoprotection | |
| RU2150271C1 (en) | Method for treating the cases of chronic prostatitis, gastric and duodenal peptic ulcer | |
| CA2031746C (en) | Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria | |
| BR9907126A (en) | Compounds and processes for the treatment of bacterial dysentery using antibiotics and toxin-binding oligosaccharide compositions | |
| KR100375342B1 (en) | A natural antimicrobial agents for the improvement of gastrointestinal disease. | |
| Rokkas et al. | Bismuth: effects on gastritis and peptic ulcer | |
| KR101971572B1 (en) | Novel Salmonella Enteritidis specific bacteriophage and antibacterial composition comprising the same | |
| KR20010022739A (en) | Fixation inhibitors for helicobacter pylori | |
| Craven | Salmonella typhimurium, hydrophobic antibiotics, and the intestinal colonization of broiler chicks | |
| Hofstra et al. | A comparative study of the effect of oral treatment with augmentin, amoxycillin and bacampicillin on the faecal flora in mice | |
| WO1994027579A1 (en) | Ulcer treating composition |